Keith S. Manchester is Director at Roivant Sciences Ltd. (ROIV). They have made 8 open-market trades across 2 companies since 2022, most recently 2026-09-16.
CIK 0001244828
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ROIV | 1,753,457 | $58.8M |
| ABUS | 46,069 | $195K |
| Total | $59.0M |
Shares reported on the most recent Form 4, priced at the 2026-09-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ROIV | SELL | 2026-06-26 | 2026-06-30 | $34.46 | $56.4M | -2.4% | -2.3% | +4.7% |
| ROIV | SELL | 2026-02-11 | 2026-02-13 | $26.64 | $32.7M | +8.2% | +7.4% | +12.0% |
| ROIV | SELL | 2025-12-16 | 2025-12-18 | $23.06 | $71.8M | -0.6% | +5.3% | +27.3% |
| ROIV | SELL | 2025-11-19 | 2025-11-21 | $20.23 | $29.8M | +5.0% | +12.4% | +36.4% |
| ROIV | SELL | 2024-09-24 | 2024-09-26 | $11.67 | $11.7M | -2.4% | +2.4% | +3.8% |
| ABUS | SELL | 2024-08-14 | 2024-08-16 | $3.69 | $33K | +3.5% | +14.5% | -2.4% |
| ROIV | SELL | 2023-09-28 | 2023-10-02 | $11.55 | $159.3M | -4.9% | -13.0% | +9.0% |
| ROIV | SELL | 2022-11-10 | 2022-11-14 | $4.75 | $37.3M | -6.2% | +31.3% | +47.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.